Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1,2,3,4,6-penta-O-galloyl-beta-D-glucose
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) is a naturally occurring polyphenolic compound and a major gallotannin found in various medicinal plants, including *Paeonia lactiflora* (peony root), *Curcuma longa* (turmeric), and *Mangifera indica* (mango). As a research compound, it has demonstrated a wide range of pharmacological activities in preclinical studies, including antioxidant, anti-inflammatory, anti-angiogenic, and anti-tumorigenic effects. Its mechanism of action is multi-targeted: it induces heme oxygenase-1 (HO-1) expression through the activation and nuclear translocation of Nrf2, inhibits the binding of vascular endothelial growth factor (VEGF) to its receptor VEGFR2 (KDR/Flk-1), modulates the GSK3β/β-catenin signaling pathway, and stabilizes p53 by inhibiting UBE2T-mediated ubiquitination. PGG is currently being investigated for potential therapeutic applications in hepatocellular carcinoma, hepatitis B virus infection, diabetic nephropathy, and neurodegenerative diseases, although it is not yet a commercial drug.
- Other names
- Pentagalloylglucose1,2,3,4,6-Pentagalloylglucosebeta-Pentagalloylglucose1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranosePentagalloyl-beta-D-glucose
02
Targets
HMOX1 (Heme oxygenase 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)VEGFR2 (Vascular endothelial growth factor receptor 2)TP53 (Cellular Tumor Antigen p53 R175H)GSK3 (Glycogen synthase kinase 3 beta)UBE2T (Ubiquitin-conjugating enzyme E2 T)
Beyond the preview
Go deeper on 1,2,3,4,6-penta-O-galloyl-beta-D-glucose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1,2,3,4,6-penta-O-galloyl-beta-D-glucose.